Company news: Novo Nordisk

Share this article:
Novo Nordisk reported first-half gains in operating profit of 13%, along with sales growth of 11% in local currencies driven by Victoza, NovoRapid and Levemir. Victoza sales were up 253% to around $444 million while sales of modern insulins were up 10% and North American sales rose 15%.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.